Colonoscopy could be costeffectiveonly in middle age

Publication
Article
Diagnostic ImagingDiagnostic Imaging Vol 30 No 12
Volume 30
Issue 12

New evidence suggests conducting screening colonoscopies for people in their mid- 50s saves money. But other evidence indicates there may be an upper age limit for the benefits of such screening.

New evidence suggests conducting screening colonoscopies for people in their mid- 50s saves money. But other evidence indicates there may be an upper age limit for the benefits of such screening.

Dr. Jianjun Li and colleagues from Maimonides Medical Center in Brooklyn conducted free screening colonoscopies for 248 consecutive patients with a mean age of 55. Follow-up detected colon cancer and large polyps in about one in 10.The screening program cost $390,000. Had these patients not been screened, their delayed treatment would have cost Medicare nearly $1.3 million. Li released results at the 2008 American College of Gastroenterology meeting.

On the other hand, the U.S. Preventive Services Task Force, an independent panel of the Department of Health and Human Services, recommended that screening cease when men reach age 75, when the possible harm from screening outweighs its benefits. The task force report was published in the Annals of Internal Medicine (2008;149[3]: 185-191).

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.